Article
Association of IL7 rs16906115 Polymorphism with Adverse Events in Patients with Advanced Lung Cancer Undergoing Immunotherapy
2026-01-13
Abstract excerpt
<h4>Background: </h4> Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (aNSCLC). However, immune-related adverse events (irAEs) remain a clinical challenge in this context. Genetic variants acting as cis-eQTLs may predict toxicity risk, thereby enabling personalized treatment. We investigated the association between the IL7 rs16906115 polymorphism, advers...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f937c2b9-7531-5b07-95cc-9299ef123234
- DOI
- 10.20944/preprints202601.0898.v1
